Informa plc (LON:INF) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Informa plc (LON:INF) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is GBX 1,093.33.

A number of research firms have recently weighed in on INF. Citigroup decreased their price target on shares of Informa from GBX 1,000 to GBX 850 and set a “neutral” rating for the company in a research report on Thursday, April 9th. JPMorgan Chase & Co. cut their price target on shares of Informa from GBX 1,300 to GBX 1,285 and set an “overweight” rating on the stock in a report on Thursday, July 2nd.

Informa Price Performance

INF stock opened at GBX 896.20 on Monday. The stock’s 50 day moving average is GBX 838.90 and its two-hundred day moving average is GBX 832.57. Informa has a 52-week low of GBX 719 and a 52-week high of GBX 1,000. The company has a market capitalization of £11.24 billion, a PE ratio of 1,120.25, a P/E/G ratio of 0.75 and a beta of 0.69. The company has a quick ratio of 1.70, a current ratio of 0.44 and a debt-to-equity ratio of 61.56.

Insider Activity

In other news, insider Stephen A. Carter purchased 222 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of GBX 809 per share, for a total transaction of £1,795.98. Also, insider Gareth Wright acquired 222 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of GBX 809 per share, with a total value of £1,795.98. 0.39% of the stock is currently owned by insiders.

Informa Company Profile

Our events, digital products and academic research services connect specialists with knowledge, helping them learn more, know more and do more.

We do this in dozens of specialist markets and subject matter categories, including in Healthcare & Pharma, Technology, Finance, Education, Marketing, Health & Nutrition, Foodservice, and many more.

And we do this through a range of products and services, including major live events, specialist media and content, expert research articles, books and open research platforms, accredited training, buyer discovery services, and digital demand and lead-generation services.